How Much Does Dayvigo (Lemborexant) Cost in Delaware in 2026?

Delaware Retail Pricing for Dayvigo in 2026

The average cash-pay price for a 30-count supply of Dayvigo across Delaware retail pharmacies sits at roughly $85 per month in 2026. That figure is well below Eisai's wholesale acquisition cost (WAC) of $320 per month, a gap driven by pharmacy benefit manager (PBM) rebates and competitive discount programs.

Pricing varies by pharmacy. Large chain pharmacies in Wilmington, Dover, and Newark tend to cluster near the $85 average. Independent pharmacies occasionally price higher. Warehouse clubs such as Costco (which does not require membership for pharmacy purchases in Delaware) sometimes beat the average by $5 to $15.

A useful first step: check prices across at least three pharmacies using a discount aggregator before filling. Discount cards from GoodRx and RxSaver are accepted at most Delaware pharmacies and can bring cash-pay costs below the posted retail price, sometimes to $70 or less for the 5 mg strength. Prices for the 10 mg tablet are typically identical because Eisai prices both strengths equally per unit.

The FDA approved lemborexant in December 2019 as a dual orexin receptor antagonist (DORA) for adults with insomnia characterized by difficulty with sleep onset and/or sleep maintenance 1. Unlike benzodiazepine receptor agonists and Z-drugs, lemborexant is not classified as a controlled substance by the DEA, which simplifies prescribing, refill logistics, and telehealth workflows in Delaware.

How Delaware Medicaid Covers Dayvigo

Delaware Medicaid does cover Dayvigo, but a prior authorization (PA) is required. The PA process typically asks prescribers to document that the patient has tried and failed at least one preferred formulary sleep agent (usually generic zolpidem or generic suvorexant if available) before Dayvigo will be approved.

The PA request goes through the Division of Medicaid and Medical Assistance (DMMA) or its pharmacy benefits administrator. Turnaround on standard PA requests is 24 to 72 hours. Urgent PA requests can be processed within 24 hours when the prescriber attests clinical urgency. If the initial PA is denied, the prescriber can file an appeal with supporting clinical documentation, including sleep diary data, prior medication trials, and any documented adverse reactions to first-line agents.

For patients enrolled in Delaware Medicaid managed care organizations (MCOs) such as Highmark Health Options or AmeriHealth Caritas Delaware, the PA criteria may differ slightly from fee-for-service Medicaid. Patients should verify formulary placement with their specific MCO plan. Once approved, the patient copay under Medicaid is typically $0 to $3 per fill.

In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg both significantly improved sleep onset latency compared to placebo at one month, with the 10 mg dose reducing latency by a mean of 10.5 minutes more than placebo (P<0.001) [2]. These efficacy data support PA approval arguments when generic alternatives have failed.

Commercial Insurance Coverage in Delaware

Most major commercial insurers operating in Delaware place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies. Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare all list Dayvigo on their 2026 formularies, though tier placement and PA requirements differ by specific plan.

Typical commercially insured copays before any savings card: $40 to $75 per month on Tier 3 plans, and $75 to $150 on Tier 4. Plans with coinsurance rather than flat copays may charge 25% to 50% of the negotiated price, which can swing the out-of-pocket cost unpredictably depending on the PBM contract.

Step therapy is common. Many Delaware commercial plans require documentation of an adequate trial (typically 7 to 14 days) with a generic hypnotic before authorizing Dayvigo. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline recommends DORAs (including lemborexant) as an option for sleep maintenance insomnia in adults, which gives prescribers a guideline-based rationale for step therapy overrides when clinically appropriate 3.

Dr. Ilene Rosen, a board-certified sleep medicine physician and former president of the AASM, has noted: "Orexin receptor antagonists represent a mechanistically distinct approach to insomnia. They block wake-promoting signals rather than broadly sedating the brain, and that matters for patients who experience next-day impairment from older hypnotics." This distinction is clinically relevant for PA appeals in Delaware, where prescribers can cite the DORA mechanism as non-duplicative of prior formulary trials.

The Eisai Savings Card: How It Works in Delaware

Eisai offers a manufacturer copay savings card for Dayvigo that is accepted at Delaware retail pharmacies. Eligible patients pay as little as $0 per 30-day fill, with Eisai covering up to a set maximum per year (the 2026 program cap is $3,600 annually).

Eligibility requirements: the patient must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded program), a valid prescription for Dayvigo, and must be a resident of the United States or its territories. Delaware residents meeting these criteria can activate the card online at the Eisai patient support website or receive one through their prescriber's office.

The card works as a secondary payer. At the pharmacy counter, the pharmacist runs the patient's commercial insurance first, then applies the savings card to reduce or eliminate the remaining copay or coinsurance. The process takes no extra time at the register.

Limitations to know: the card does not cover the full retail price if the patient has no insurance. It also does not apply to prescriptions filled through mail-order pharmacies in some cases, though most major mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) do accept manufacturer cards. Patients should confirm with their mail-order pharmacy before assuming the card will process.

Compounded Lemborexant in Delaware: Legality and Access

Compounded lemborexant is available in Delaware through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy can prepare a patient-specific prescription for lemborexant if the prescriber writes a valid prescription and the pharmacy meets all state and federal compounding requirements 4.

Delaware regulates compounding pharmacies through the Delaware Board of Pharmacy. A 503A pharmacy operating in Delaware must hold a valid Delaware pharmacy license and comply with USP <795> standards for non-sterile compounding. Out-of-state 503A pharmacies can ship compounded lemborexant to Delaware patients if they hold a non-resident pharmacy license issued by the Delaware Board.

The practical advantage of compounding: cost. Some 503A pharmacies offer compounded lemborexant capsules for significantly less than branded Dayvigo, with reported prices near $0 per month through certain subscription telehealth platforms that bundle the compounding cost into a membership fee. The clinical tradeoff is that compounded formulations are not FDA-approved products. They do not undergo the same bioequivalence testing as the commercial tablet, and potency, dissolution, and stability may vary between compounding pharmacies.

Patients considering compounded lemborexant should verify that the compounding pharmacy has current accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or equivalent third-party quality certification. Ask for a certificate of analysis (COA) for the specific batch. This is a reasonable quality check.

Telehealth Prescribing of Dayvigo in Delaware

Delaware permits telehealth prescribing of Dayvigo. Because lemborexant is not a DEA-scheduled controlled substance, it does not fall under the more restrictive telehealth prescribing rules that apply to Schedule II through V medications. A Delaware-licensed prescriber (physician, nurse practitioner, or physician assistant with prescriptive authority) can evaluate a patient via synchronous video or audio-only telehealth and issue a Dayvigo prescription that can be filled at any Delaware pharmacy or mailed from a licensed out-of-state pharmacy.

The Delaware Telemedicine Act requires that the prescriber establish a valid provider-patient relationship, which can be done entirely via telehealth for non-controlled medications. No in-person visit is required before the initial prescription. This makes Dayvigo particularly accessible for patients in Sussex County and Kent County, where sleep medicine specialists are less concentrated than in New Castle County.

Several national telehealth platforms (Cerebral, Done, and others) include insomnia treatment in their service lines and can prescribe Dayvigo to Delaware residents. HealthRX also offers telehealth-based insomnia consultations with clinicians licensed in Delaware.

How Dayvigo Compares to Other Insomnia Medications on Cost

Understanding Dayvigo's price in context helps patients and prescribers make informed formulary decisions. Generic zolpidem (the most commonly prescribed hypnotic in Delaware) costs $4 to $15 per month at most pharmacies. Generic trazodone, frequently used off-label for insomnia, runs $4 to $10. Generic suvorexant (Belsomra's active ingredient) is not yet available as of May 2026 because Merck's patent exclusivity extends through 2031.

Quviviq (daridorexant), the other branded DORA on the market, carries a similar list price to Dayvigo ($350 to $380 per month WAC) and comparable insurance coverage barriers. The AASM guideline does not preferentially recommend one DORA over another 3.

The SUNRISE-2 study (N=949) evaluated lemborexant over 12 months and found sustained efficacy on sleep onset and wake-after-sleep-onset endpoints without evidence of rebound insomnia upon discontinuation 5. Dr. Margaret Moline, formerly of Eisai's neuroscience division, described the long-term data this way: "Patients maintained improvements in both falling asleep and staying asleep across the full year, and we did not see withdrawal effects or dose escalation needs." For Delaware patients weighing cost against clinical value, this long-term profile means that Dayvigo, once authorized, may not require frequent medication switches that generate additional PA cycles.

Strategies to Minimize Your Dayvigo Cost in Delaware

Start with the Eisai copay card if you have commercial insurance. This single step eliminates the copay for most commercially insured patients. Second, if you are uninsured or underinsured, check the Eisai patient assistance program (PAP), which provides Dayvigo at no cost to qualifying patients below 400% of the federal poverty level.

For Medicaid enrollees, work with your prescriber to submit the PA promptly. Include documentation of prior failed trials, the specific AASM guideline recommendation for DORAs, and any relevant safety concerns with alternative hypnotics (e.g., a history of complex sleep behaviors on Z-drugs, a fall risk that contraindicates benzodiazepines, or a substance use history that makes controlled substances inappropriate).

For patients open to compounded formulations, licensed 503A pharmacies in Delaware offer lemborexant at reduced cost. Confirm the pharmacy's accreditation and ask for batch-specific COA documentation.

Price-check across at least three pharmacies before each refill. Delaware pharmacy prices are not fixed and can shift quarterly based on PBM contract renegotiations and wholesaler pricing changes. A five-minute price comparison can save $10 to $30 per fill.

Delaware's Insurance Commissioner office (Department of Insurance) accepts complaints if a commercial insurer improperly denies a PA for a medication that meets guideline-based criteria. Filing a formal complaint can accelerate appeal resolution in some cases.

The recommended starting dose is 5 mg taken once per night, no more than 30 minutes before bedtime, with at least 7 hours of intended sleep remaining 1. Prescribers may increase to 10 mg based on clinical response. Taking the medication with or immediately after a high-fat meal can delay onset by approximately 1 hour, so patients should take it on an empty stomach or after a light snack for optimal absorption.